Original Article

You have full text access to this OnlineOpen article

Multimodality therapy for locoregional extrahepatic cholangiocarcinoma†‡

A population-based analysis

  1. Clifton D. Fuller MD1,2,3,§,*,
  2. Samuel J. Wang MD, PhD3,
  3. Mehee Choi MD3,
  4. Brian G. Czito MD4,
  5. John Cornell PhD5,
  6. Tania M. Welzel MD, MHS6,
  7. Katherine A. McGlynn PhD, MPH6,
  8. Join Y. Luh MD1,7,
  9. Charles R. Thomas Jr MD3

Article first published online: 27 JUL 2009

DOI: 10.1002/cncr.24572

Issue

Cancer

Cancer

Volume 115, Issue 22, pages 5175–5183, 15 November 2009

Additional Information

How to Cite

Fuller, C. D., Wang, S. J., Choi, M., Czito, B. G., Cornell, J., Welzel, T. M., McGlynn, K. A., Luh, J. Y. and Thomas, C. R. (2009), Multimodality therapy for locoregional extrahepatic cholangiocarcinoma. Cancer, 115: 5175–5183. doi: 10.1002/cncr.24572

Author Information

  1. 1

    Department of Radiation Oncology, The University of Texas Health Science Center at San Antonio, San Antonio, Texas

  2. 2

    Graduate Division of Radiological Sciences/Department of Radiology, The University of Texas Health Science Center at San Antonio, San Antonio, Texas

  3. 3

    Department of Radiation Medicine, Oregon Health Sciences University Cancer Institute, Portland, Oregon

  4. 4

    Department of Radiation Oncology, Duke University, Durham, North Carolina

  5. 5

    Department of Epidemiology and Biostatistics, The University of Texas Health Science Center at San Antonio, San Antonio, Texas

  6. 6

    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland

  7. 7

    St. Joseph Hospital, Eureka, California

  1. §

    Fax: (210) 450-5085

*Department of Radiation Oncology, and Graduate Division of Radiological Sciences/Department of Radiology, The University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, MSC 7889, San Antonio, TX 78229

  1. †

    Preliminary versions of these analyses were presented at the American Society of Therapeutic Radiology and Oncology Annual Meeting, Los Angeles, California, October 28-November 1, 2007 and the American Radium Society Meeting, Vancouver, British Columbia, Canada, April 25-29, 2009.

  2. ‡

    This article is a US Government work and, as such, is in the public domain in the United States of America.

Publication History

  1. Issue published online: 3 NOV 2009
  2. Article first published online: 27 JUL 2009
  3. Manuscript Accepted: 3 FEB 2009
  4. Manuscript Revised: 28 JAN 2009
  5. Manuscript Received: 9 OCT 2008

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (340K)

References

  • 1
    Welzel TM, McGlynn KA, Hsing AW, O'Brien TR, Pfeiffer RM. Impact of classification of hilar cholangiocarcinomas (Klatskin tumors) on the incidence of intra- and extrahepatic cholangiocarcinoma in the United States. J Natl Cancer Inst. 2006; 98: 873-875.
  • 2
    Fuller C, Diehl A. Epidemiology of gallbladder and biliary tract cancer. In: Thomas CR, Fuller CD, eds. Biliary Tract and Gallbladder Cancer: Diagnosis and Therapy. New York, NY: Demos; 2008; 3-18.
  • 3
    Vallis KA, Benjamin IS, Munro AJ, et al. External beam and intraluminal radiotherapy for locally advanced bile duct cancer: role and tolerability. Radiother Oncol. 1996; 41: 61-66.
  • 4
    Curley SA. Diagnosis and management of intrahepatic and extrahepatic cholangiocarcinoma. Cancer Treat Res. 2001;x 109: 117-144.
  • 5
    Jarnagin WR, Shoup M. Surgical management of cholangiocarcinoma. Semin Liver Dis. 2004; 24: 189-199.
  • 6
    Yalcin S. Diagnosis and management of cholangiocarcinomas: a comprehensive review. Hepatogastroenterology. 2004; 51: 43-50.
  • 7
    Ben-David MA, Griffith KA, Abu-Isa E, et al. External-beam radiotherapy for localized extrahepatic cholangiocarcinoma. Int J Radiat Oncol Biol Phys. 2006; 66: 772-779.
  • 8
    Jarnagin WR. Cholangiocarcinoma of the extrahepatic bile ducts. Semin Surg Oncol. 2000; 19: 156-176.
    Direct Link:
  • 9
    McMasters KM, Tuttle TM, Leach SD, et al. Neoadjuvant chemoradiation for extrahepatic cholangiocarcinoma. Am J Surg. 1997; 174: 605-608; discussion 608-609.
  • 10
    Crane CH, Macdonald KO, Vauthey JN, et al. Limitations of conventional doses of chemoradiation for unresectable biliary cancer. Int J Radiat Oncol Biol Phys. 2002; 53: 969-974.
  • 11
    Fuss M, Salter BJ, Cavanaugh SX, et al. Daily ultrasound-based image-guided targeting for radiotherapy of upper abdominal malignancies. Int J Radiat Oncol Biol Phys. 2004; 59: 1245-1256.
  • 12
    Heron DE, Stein DE, Eschelman DJ, et al. Cholangiocarcinoma: the impact of tumor location and treatment strategy on outcome. Am J Clin Oncol. 2003; 26: 422-428.
  • 13
    Itoh H, Nishijima K, Kurosaka Y, et al. Magnitude of combination therapy of radical resection and external beam radiotherapy for patients with carcinomas of the extrahepatic bile duct and gallbladder. Dig Dis Sci. 2005; 50: 2231-2242.
  • 14
    Tsujino K, Landry JC, Smith RG, Keller JW, Williams WH, Davis LW. Definitive radiation therapy for extrahepatic bile duct carcinoma. Radiology. 1995; 196: 275-280.
  • 15
    Kamada T, Saitou H, Takamura A, Nojima T, Okushiba SI. The role of radiotherapy in the management of extrahepatic bile duct cancer: an analysis of 145 consecutive patients treated with intraluminal and/or external beam radiotherapy. Int J Radiat Oncol Biol Phys. 1996; 34: 767-774.
  • 16
    Fields JN, Emami B. Carcinoma of the extrahepatic biliary system—results of primary and adjuvant radiotherapy. Int J Radiat Oncol Biol Phys. 1987; 13: 331-338.
  • 17
    National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program, Cancer Statistics Branch. Surveillance, Epidemiology, and End Results program database. Available at: http://www.seer.cancer.gov/ Accessed in May 2008.
  • 18
    Royston P. The lognormal distribution as a model for survival time in cancer, with an emphasis on prognostic factors. Stat Neerl. 2001; 55: 89-104.
    Direct Link:
  • 19
    Ahmed FE, Vos PW, Holbert D. Modeling survival in colon cancer: a methodological review. Mol Cancer. 2007; 6: 15.
  • 20
    Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457-481.
  • 21
    Cox DR. Regression and life tables (with discussion). J R Stat Soc B. 1972; 34: 187-200.
  • 22
    Grambsch PM, Therneau TM, Fleming TR. Diagnostic plots to reveal functional form for covariates in multiplicative intensity models. Biometrics. 1995; 51: 1469-1482.
  • 23
    Schoenthaler R, Phillips TL, Castro J, Efird JT, Better A, Way LW. Carcinoma of the extrahepatic bile ducts. The University of California at San Francisco experience. Ann Surg. 1994; 219: 267-274.
  • 24
    Nakeeb A, Tran KQ, Black MJ, et al. Improved survival in resected biliary malignancies. Surgery. 2002; 132: 555-563; discussion 563-564.
  • 25
    Nelson JW, Ghafoori AP, Willett CG, et al. Concurrent chemoradiotherapy in resected extrahepatic cholangiocarcinoma. Int J Radiat Oncol Biol Phys. 2009; 73: 148-153.
  • 26
    Punglia RS, Morrow M, Winer EP, Harris JR. Local therapy and survival in breast cancer. N Engl J Med. 2007; 356: 2399-2405.
  • 27
    Pitt HA, Nakeeb A, Abrams RA, et al. Perihilar cholangiocarcinoma. Postoperative radiotherapy does not improve survival. Ann Surg. 1995; 221: 788-797; discussion 97-98.
  • 28
    Stein DE, Heron DE, Rosato EL, Anne PR, Topham AK. Positive microscopic margins alter outcome in lymph node-negative cholangiocarcinoma when resection is combined with adjuvant radiotherapy. Am J Clin Oncol. 2005; 28: 21-23.
  • 29
    Todoroki T. Radiotherapy as a component of multidisciplinary treatment of bile duct cancer: a surgeon's perspective. J Hepatobiliary Pancreat Surg. 2001; 8: 130-136.
  • 30
    Todoroki T, Ohara K, Kawamoto T, et al. Benefits of adjuvant radiotherapy after radical resection of locally advanced main hepatic duct carcinoma. Int J Radiat Oncol Biol Phys. 2000; 46: 581-587.
  • 31
    Zlotecki RA, Jung LA, Vauthey JN, Vogel SB, Mendenhall WM. Carcinoma of the extrahepatic biliary tract: surgery and radiotherapy for curative and palliative intent. Radiat Oncol Investig. 1998; 6: 240-247.
    Direct Link:
  • 32
    Schoenthaler R, Castro JR, Halberg FE, Phillips TL. Definitive postoperative irradiation of bile duct carcinoma with charged particles and/or photons. Int J Radiat Oncol Biol Phys. 1993; 27: 75-82.
  • 33
    Veeze-Kuijpers B, Meerwaldt JH, Lameris JS, van Blankenstein M, van Putten WL, Terpstra OT. The role of radiotherapy in the treatment of bile duct carcinoma. Int J Radiat Oncol Biol Phys. 1990; 18: 63-67.
  • 34
    Alden ME, Waterman FM, Topham AK, Barbot DJ, Shapiro MJ, Mohiuddin M. Cholangiocarcinoma: clinical significance of tumor location along the extrahepatic bile duct. Radiology. 1995; 197: 511-516.
  • 35
    DeOliveira ML, Cunningham SC, Cameron JL, et al. Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. Ann Surg. 2007; 245: 755-762.
  • 36
    Nakeeb A, Pitt HA, Sohn TA, et al. Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors. Ann Surg. 1996; 224: 463-473; discussion 473-475.
  • 37
    Nathan H, Pawlik TM, Wolfgang CL, Choti MA, Cameron JL, Schulick RD. Trends in survival after surgery for cholangiocarcinoma: a 30-year population-based SEER database analysis. J Gastrointest Surg. 2007; 11: 1488-1496; discussion 1496-1497.
  • 38
    Kaido T, Imamura M. Unresectable hilar cholangiocarcinoma completely reduced by external radiation therapy. Hepatogastroenterology. 2005; 52: 725-727.
  • 39
    Birkmeyer JD, Sun Y, Wong SL, Stukel TA. Hospital volume and late survival after cancer surgery. Ann Surg. 2007; 245: 777-783.
  • 40
    Wong SL, Wei Y, Birkmeyer JD. Use of adjuvant radiotherapy at hospitals with and without on-site radiation services. Cancer. 2007; 109: 796-801.
    Direct Link:
  • 41
    Chapman JW, Hanna W, Kahn HJ, et al. Alternative multivariate modelling for time to local recurrence for breast cancer patients receiving a lumpectomy alone. Surg Oncol. 1996; 5: 265-271.
  • 42
    McCready DR, Chapman JA, Hanna WM, et al. Factors affecting distant disease-free survival for primary invasive breast cancer: use of a log-normal survival model. Ann Surg Oncol. 2000; 7: 416-426.
  • 43
    Tai P, Chapman JA, Yu E, et al. Disease-specific survival for limited-stage small-cell lung cancer affected by statistical method of assessment. BMC Cancer. 2007; 7: 31.
  • 44
    Boag J. Maximum likelihood estimates of the proportion of patients cured by cancer therapy. J R Stat Soc B. 1949; 11: 15-44.
  • 45
    Gamel JW, Vogel RL. Comparison of parametric and non-parametric survival methods using simulated clinical data. Stat Med. 1997; 16: 1629-1643.
    Direct Link:
  • 46
    Mould RF, Boag JW. A test of several parametric statistical models for estimating success rate in the treatment of carcinoma cervix uteri. Br J Cancer. 1975; 32: 529-550.
  • 47
    Gore SM, Pocock SJ, Kerr GR. Regression models and non-proportional hazards in the analysis of breast cancer survival. Appl Stat. 1984; 33: 176-195.
  • 48
    Wang SJ, Fuller CD, Kim JS, Sittig DF, Thomas CRJr, Ravdin PM. Prediction model for estimating the survival benefit of adjuvant radiotherapy for gallbladder cancer. J Clin Oncol. 2008; 26: 2112-2117.
  • 49
    Shinohara ET, Mitra N, Guo M, Metz JM. Radiation therapy is associated with improved survival in the adjuvant and definitive treatment of intrahepatic cholangiocarcinoma. Int J Radiat Oncol Biol Phys. 2008; 72: 1495-1501.
  • 50
    Shinohara ET, Mitra N, Guo M, Metz JM. Radiation therapy is associated with improved survival in the adjuvant and definitive treatment of intrahepatic cholangiocarcinoma. Int J Radiat Oncol Biol Phys. In press
  • 51
    Jarnagin WR, Ruo L, Little SA, et al. Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma: implications for adjuvant therapeutic strategies. Cancer. 2003; 98: 1689-1700.
    Direct Link:
  • 52
    Park SW, Park YS, Chung JB, et al. Patterns and relevant factors of tumor recurrence for extrahepatic bile duct carcinoma after radical resection. Hepatogastroenterology. 2004; 51: 1612-1618.
  • 53
    de Castro SM, Kuhlmann KF, van Heek NT, et al. Recurrent disease after microscopically radical (R0) resection of periampullary adenocarcinoma in patients without adjuvant therapy. J Gastrointest Surg. 2004; 8: 775-784; discussion 784.
  • 54
    Hughes MA, Frassica DA, Yeo CJ, et al. Adjuvant concurrent chemoradiation for adenocarcinoma of the distal common bile duct. Int J Radiat Oncol Biol Phys. 2007; 68: 178-182.
  • 55
    Cameron JL, Pitt HA, Zinner MJ, Kaufman SL, Coleman J. Management of proximal cholangiocarcinomas by surgical resection and radiotherapy. Am J Surg. 1990; 159: 91-97; discussion 97-98.
  • 56
    Gerhards MF, van Gulik TM, Gonzalez Gonzalez D, Rauws EA, Gouma DJ. Results of postoperative radiotherapy for resectable hilar cholangiocarcinoma. World J Surg. 2003; 27: 173-179.
  • 57
    Czito BG, Fuller CD. Radiation therapy. In: Thomas CR, Fuller CD, eds. Biliary Tract and Gallbladder Cancer: Diagnosis and Therapy. New York, NY: Demos; 2008: 217-235.
View Full Article (HTML) Get PDF (340K)